478 related articles for article (PubMed ID: 16914693)
41. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
[TBL] [Abstract][Full Text] [Related]
42. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.
Barkhof F; Rocca M; Francis G; Van Waesberghe JH; Uitdehaag BM; Hommes OR; Hartung HP; Durelli L; Edan G; Fernández O; Seeldrayers P; Sørensen P; Margrie S; Rovaris M; Comi G; Filippi M;
Ann Neurol; 2003 Jun; 53(6):718-24. PubMed ID: 12783417
[TBL] [Abstract][Full Text] [Related]
43. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Clerico M; Faggiano F; Palace J; Rice G; Tintorè M; Durelli L
Cochrane Database Syst Rev; 2008 Apr; (2):CD005278. PubMed ID: 18425915
[TBL] [Abstract][Full Text] [Related]
44. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference.
Lublin FD; Whitaker JN; Eidelman BH; Miller AE; Arnason BG; Burks JS
Neurology; 1996 Jan; 46(1):12-8. PubMed ID: 8559358
[TBL] [Abstract][Full Text] [Related]
45. Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study.
D'Alessandro R; Vignatelli L; Lugaresi A; Baldin E; Granella F; Tola MR; Malagù S; Motti L; Neri W; Galeotti M; Santangelo M; Fiorani L; Montanari E; Scandellari C; Benedetti MD; Leone M
J Neurol; 2013 Jun; 260(6):1583-93. PubMed ID: 23377434
[TBL] [Abstract][Full Text] [Related]
46. Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.
Sombekke MH; Wattjes MP; Balk LJ; Nielsen JM; Vrenken H; Uitdehaag BM; Polman CH; Barkhof F
Neurology; 2013 Jan; 80(1):69-75. PubMed ID: 23243070
[TBL] [Abstract][Full Text] [Related]
47. Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria.
Habek M; Pavičić T; Ruška B; Pavlović I; Gabelić T; Barun B; Adamec I; Crnošija L; Krbot Skorić M
Mult Scler Relat Disord; 2018 Oct; 25():99-103. PubMed ID: 30059896
[TBL] [Abstract][Full Text] [Related]
48. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
Kappos L; Edan G; Freedman MS; Montalbán X; Hartung HP; Hemmer B; Fox EJ; Barkhof F; Schippling S; Schulze A; Pleimes D; Pohl C; Sandbrink R; Suarez G; Wicklein EM;
Neurology; 2016 Sep; 87(10):978-87. PubMed ID: 27511182
[TBL] [Abstract][Full Text] [Related]
49. Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group.
Zhao GJ; Koopmans RA; Li DK; Bedell L; Paty DW
Neurology; 2000 Jan; 54(1):200-6. PubMed ID: 10636148
[TBL] [Abstract][Full Text] [Related]
50. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.
Soilu-Hänninen M; Aivo J; Lindström BM; Elovaara I; Sumelahti ML; Färkkilä M; Tienari P; Atula S; Sarasoja T; Herrala L; Keskinarkaus I; Kruger J; Kallio T; Rocca MA; Filippi M
J Neurol Neurosurg Psychiatry; 2012 May; 83(5):565-71. PubMed ID: 22362918
[TBL] [Abstract][Full Text] [Related]
51. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999
[TBL] [Abstract][Full Text] [Related]
53. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Paty DW; Li DK
Neurology; 1993 Apr; 43(4):662-7. PubMed ID: 8469319
[TBL] [Abstract][Full Text] [Related]
54. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.
Comi G; Martinelli V; Rodegher M; Moiola L; Leocani L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Preziosa P; Ravnborg M; Rieckmann P; Rocca MA; Wynn D; Young C; Filippi M
Mult Scler; 2013 Jul; 19(8):1074-83. PubMed ID: 23234810
[TBL] [Abstract][Full Text] [Related]
55. Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis.
Siddiqui MA; Wellington K
CNS Drugs; 2005; 19(1):55-61; discussion 63-4. PubMed ID: 15651905
[TBL] [Abstract][Full Text] [Related]
56. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
[TBL] [Abstract][Full Text] [Related]
57. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
[TBL] [Abstract][Full Text] [Related]
58. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
[TBL] [Abstract][Full Text] [Related]
59. [Brain MRI findings in Japanese patients with clinically isolated syndrome].
Tanaka M; Motoyama R; Tahara M; Tanaka K
Rinsho Shinkeigaku; 2012; 52(10):725-9. PubMed ID: 23064621
[TBL] [Abstract][Full Text] [Related]
60. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
Jacobs LD; Beck RW; Simon JH; Kinkel RP; Brownscheidle CM; Murray TJ; Simonian NA; Slasor PJ; Sandrock AW
N Engl J Med; 2000 Sep; 343(13):898-904. PubMed ID: 11006365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
